drug
Hemophilia A
Preclinicalupdated 6mo agoby Sernova Biotherapeutics Inc
Preclinicalcommunity read0 votes
🐶 often sniffed alongside
top 7all catalysts(0)
nothing on the calendar yet
News(10)
- Novo’s CEO still looking for deals to ‘close some of the gaps,’ as misfires hit profitsNovo’s CEO has told Fierce that the company remains on the hunt for deals that “close some of the gaps” in its pipeline, as the Big Pharma reports billions of dollars in impairment charges from a s…fiercebiotech · 13d ago
- Sanofi targets late-phase and commercial M&A to offset looming Dupixent declineFocused on ensuring growth beyond Dupixent, Sanofi wants to acquire derisked assets that may benefit from the French pharma’s commercial capabilities, executives said on Friday as they reported thi…biospace · 17d ago
- Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T assetAside from RG6540, Roche also discontinued a host of other early-stage assets, including an antisense oligonucleotide for Alzheimer’s disease and a small-molecule candidate for geographic atrophy.biospace · 25d ago
- FDA extends review of Novo’s hemophilia A drug, citing manufacturing issuesDespite the regulatory delay, Novo is still expecting a 2027 launch for its hemophilia A drug denecimig.biospace · 1mo ago
- FDA delays Novo’s hemophilia A drug review over factory issuesUS regulators have extended their review of Novo's hemophilia A injection denecimig because of issues at an unnamed manufacturing facility. The FDA attributed the delay to “ongoing facility remedia…endpoints · 1mo ago
- STAT+: Pharmalittle: We’re reading about a Vaxcyte pneumococcal shot, increasing pharma M&A, and moreVaxcyte said its pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up a competition with Pfizer and Merckstat · 1mo ago
- CHMP backs Novo’s hemophilia A drug and seven other medicinesNovo won regulatory backing for its hemophilia A preventive drug from the European Medicines Agency's human medicines committee, which also recommended approving seven other new drugs and 11 label…endpoints · 1mo ago
- Roche, Dualitas team up to find bispecific drugs for immune diseasesThrough a research deal worth up to $1 billion, Dualitas will sift through more than 300,000 possible bispecific combinations in the hopes of unearthing new and differentiating treatments.biopharma_dive · 2mo ago
- Roche signs $1B deal with Dualitas to pair up on big bispecific screening driveRoche is paying Dualitas Therapeutics $36.5 million upfront to screen over 300,000 novel bispecific combinations in search of new treatments for immunology and inflammation diseases.fiercebiotech · 2mo ago
- Oz says ‘AI-based avatars’ can help rural communities. Some leaders disagreeFeds invest in AI for heart failure, vaccines and this year's midterms, and more health news from Morning Roundsstat · 2mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that